About Oxidoreductase NAD-binding domain-containing protein 1
Oxidoreductase NAD-binding domain-containing protein 1 (OXNAD1) is a protein
from Homo sapiens identified by UniProt accession
Q96HP4, 312 residues long.
MolForge cross-references it against 0 known binders and
11 disease associations.
Target properties
| Protein name | Oxidoreductase NAD-binding domain-containing protein 1 |
|---|
| UniProt accession | Q96HP4 |
|---|
| Gene | OXNAD1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 312 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (11)
Diseases linked to this target (Open Targets).
- diffuse plaque measurement · score 0.04
- Sepsis · score 0.01
- neoplasm · score 0.01
- melanoma · score 0.01
- sarcoidosis · score 0.00
- skin basal cell carcinoma · score 0.00
- pulmonary arterial hypertension · score 0.00
- basal cell carcinoma · score 0.00
- cancer · score 0.00
- meningococcal infection · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q96HP4-F1 | alphafold | PREDICTED | 87.34 | — |
Amino-acid sequence (312 residues)
MACAAVMIPG LLRCSVGAIR IEAASLRLTL STLRHLTLTS IMKSKRKTDH MERTASVLRR EIVSAAKVCG AASESPSVKS LRLLVADQDF SFKAGQWVDF FIPGVSVVGG FSICSSPRLL EQERVIELAV KYTNHPPALW VHNTCTLDCE VAVRVGGEFF FDPQPADASR NLVLIAGGVG INPLLSILRH AADLLREQAN KRNGYEIGTI KLFYSAKNTS ELLFKKNILD LVNEFPEKIA CSLHVTKQTT QINAELKPYI TEGRITEKEI RDHISKETLF YICGPPPMTD FFSKQLENNH VPKEHICFEK WW
Explore Oxidoreductase NAD-binding domain-containing protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets